IP Library Granted Patent US 10,835,598
Granted Patent B2
US 10,835,598 · App. 15/582,133 · Granted Nov 17, 2020

Prophylactic protection against viral infections, particularly HIV

Inventors: Jamie Sulley (La Jolla, CA); Luis Squiquera (Buenos Aires, AR); David Sidransky (Pikesville, MD); Tom Hodge (Athens, GA)
Assignee: ORGENESIS INC.
A61K39/21A61K9/0014A61K9/0034A61K35/744A61K35/747A61K38/465C07K7/08C07K14/16C12N9/22C12N15/86C12Y301/27005A61K38/00A61K39/00A61K48/00A61K2039/525A61K2039/53C12N2740/16043C12N2740/16334C12Y301/27
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,835,598
App. No.
15/582,133
Granted
Nov 17, 2020
Kind
B2
Abstract

An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.

Claims (2)

1. A method of diminishing the susceptibility of an individual to an HIV infection, comprising the step of topically applying to the individual a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease and a viscous vehicle that does not unacceptably interfere with the enzymatic activity, wherein the ribonuclease is ranpirnase, and wherein the pharmaceutical composition is topically applied to body regions that might be exposed to HIV during sexual intercourse.

2. The method of claim 1 , wherein the ribonuclease is selected from the group consisting of ranpirnase (SEQ ID NO:1) and the '805 ranpirnase variant (SEQ ID NO:2).

Assignments (3)
FINAL JUDGMENT, WRIT OF EXECUTION AND JUDGMENT LIEN CERTIFICATE Recorded Aug 20, 2025
From: ORGENESIS INC.
To: BACAL, MURRAY
Reel/Frame 072485/0057 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2020
From: TAMIR BIOTECHNOLOGY, INC.
To: ORGENESIS INC.
Reel/Frame 052892/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: SULLEY, JAMIE; SQUIQUERA, LUIS; SIDRANSKY, DAVID; HODGE, TOM
To: TAMIR BIOTECHNOLOGY, INC.
Reel/Frame 052256/0582 →
Continuity (4)
Continuation In Part 14793920 · Jul 8, 2015
Continuation In Part 14462520 · Aug 18, 2014
Provisional Application 62367050 · Jul 26, 2016
Related Publication 20170296647A1 · Oct 19, 2017